Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Study of Tissue and Blood Samples From Patients With High-Grade Glioma

NCT01004887 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tissue and blood samples from patients with high-grade glioma.

Interventions

  • OTHER diagnostic laboratory biomarker analysis

Study Locations (20)

Illinois

  • Illinois CancerCare - Bloomington — Bloomington
  • St. Joseph Medical Center — Bloomington
  • Graham Hospital — Canton
  • Illinois CancerCare - Canton — Canton
  • Illinois CancerCare - Carthage — Carthage
  • Memorial Hospital — Carthage
  • Eureka Community Hospital — Eureka
  • Illinois CancerCare - Eureka — Eureka
  • Galesburg Clinic, PC — Galesburg
  • Illinois CancerCare - Galesburg — Galesburg
  • Illinois CancerCare - Havana — Havana
  • Mason District Hospital — Havana
  • Illinois CancerCare - Kewanee Clinic — Kewanee
  • Illinois CancerCare - Macomb — Macomb
  • McDonough District Hospital — Macomb
  • Trinity Cancer Center at Trinity Medical Center - 7th Street Campus — Moline

Arizona

  • Mayo Clinic Scottsdale — Scottsdale

Connecticut

  • Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center — Hartford

Florida

  • Mayo Clinic - Jacksonville — Jacksonville

Idaho

  • Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center — Boise

Trial Details

FieldValue
Enrollment Target 631 participants
Start Date 1995-11
Est. Completion 2019-01-15

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01004887

The ClinicalTrials.gov registry entry for NCT01004887 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 631 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 147 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention — of which diagnostic laboratory biomarker analysis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01004887 reports 20 study locations spanning 5 distinct geographic areas — top geographies include Illinois, Arizona, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01004887 about?

NCT01004887 is a clinical study titled "Study of Tissue and Blood Samples From Patients With High-Grade Glioma". RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research st...

What is the current status of trial NCT01004887?

This trial is currently completed. The enrollment target is 631 participants. The study started on 1995-11. Estimated completion is 2019-01-15.

What conditions does trial NCT01004887 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01004887?

The interventions under investigation include: diagnostic laboratory biomarker analysis (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01004887?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 147 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01004887 being conducted?

This trial has 20 study locations across Arizona, Connecticut, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial